Skip to main content
. Author manuscript; available in PMC: 2007 Jul 6.
Published in final edited form as: Bone Marrow Transplant. 2006 Sep 4;38(8):539–546. doi: 10.1038/sj.bmt.1705488

Figure 3.

Figure 3

Survival curves showing the absolute risk reductions in death during the first 6 years of transplant with allogeneic PBSC vs BM depending on whether four doses of MTX (a) or three doses of MTX (b) were given. There was statistically better survival among recipients of PBSC compared to BM in the four dose MTX studies. No statistically significant differences were seen among recipients of PBSC or BM in the three dose trials. Differences in 5-year outcome, together with the standard errors, and two-sided P-value are given in the box.